This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

28/100

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Canada’s Drug Agency (CDA-AMC) recommends that Leqembi be reimbursed by public drug plans for the treatment of adult patients in the early stages of Alzheimer disease (AD) (i.e., mild cognitive impairment [MCI] or mild dementia) who have evidence of amyloid in the brain and who are APOE epsilon 4 (APOE4) noncarriers or heterozygotes, if certain conditions are met. Leqembi should only be covered to treat adult patients aged 50 years or older who have a clinical diagnosis of early AD with confirmed amyloid pathology using a validated method, and who are APOE4 noncarriers or heterozygotes. Leqembi should only be reimbursed if prescribed by clinicians with expertise and experience in the diagnosis, management, and treatment of AD, in a setting with timely access to MRI. Treatment should not be initiated, and should be discontinued, in patients who are unable or unwilling to undergo the recommended MRI monitoring for amyloid-related imaging abnormalities (ARIAs). Leqembi should only be used in patients without symptomatic ARIAs or moderate to severe radiographic ARIAs, and if the cost of Leqembi is reduced. Leqembi should not be reimbursed in combination with other monoclonal antibody therapies for AD or upon disease progression to moderate dementia.

Key findings

Leqembi should only be covered to treat adult patients aged 50 years or older who have a clinical diagnosis of early AD with confirmed amyloid pathology using a validated method, and who are APOE4 noncarriers or heterozygotes.
Leqembi should only be reimbursed if prescribed by clinicians with expertise and experience in the diagnosis, management, and treatment of AD, in a setting with timely access to MRI.
Treatment should not be initiated, and should be discontinued, in patients who are unable or unwilling to undergo the recommended MRI monitoring for amyloid-related imaging abnormalities (ARIAs).
Leqembi should only be used in patients without symptomatic ARIAs or moderate to severe radiographic ARIAs, and if the cost of Leqembi is reduced.
Leqembi should not be reimbursed in combination with other monoclonal antibody therapies for AD or upon disease progression to moderate dementia.

Why it matters

Canada's Drug Agency recommends public reimbursement of Leqembi only for adults 50 or older in the early stages of Alzheimer disease with confirmed amyloid who are APOE4 noncarriers or heterozygotes, and only if certain conditions are met. Treatment should not be started or continued in patients unable or unwilling to undergo the recommended MRI monitoring for ARIAs, and should not be reimbursed in combination with other monoclonal antibody therapies for Alzheimer disease or after progression to moderate dementia.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 28/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 26 of the 93 points we could judge it on, which is 28 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Canadian Journal of Health Technologies)
Journal's citation record	0 / 4	Canadian Journal of Health Technologies: journal h-index 12 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 2 year(s) since 2026
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author CDA-AMC holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multi-centre collaboration	0 / 3	OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	26 / 93	Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 26 of the 93 points we could judge it on is 28 out of 100.
Total	28 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

CDA-AMC. (2026). Lecanemab (Leqembi). Canadian Journal of Health Technologies. https://doi.org/10.51731/cjht.2026.1514

Vancouver

CDA-AMC. Lecanemab (Leqembi). Canadian Journal of Health Technologies. 2026. doi:10.51731/cjht.2026.1514.

BibTeX

@article{cdaamc2026-25dfc5ad,
  author  = {CDA-AMC},
  title   = {{Lecanemab (Leqembi)}},
  journal = {Canadian Journal of Health Technologies},
  year    = {2026},
  doi     = {10.51731/cjht.2026.1514},
  url     = {https://doi.org/10.51731/cjht.2026.1514}
}

Related studies in Treatments

Similar studies

More on Treatments

Where this led: Lecanemab on the treatments page — its current status, approval date, side-effect rate and list price, kept up to date.

See all studies in Treatments →